Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients

Lancet

Volumn 349, Issue 9052, 1997, Pages 594-598

  Alderman, Michael H ^a   Cohen, Hillel ^a   Roqué, Rosemarie ^a   Madhavan, Shantha ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY RISK; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

EID: 0031053865     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)08359-6     Document Type: Article

References (18)

1. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274 620-25.
2. Pahor M, Guralnik JM, Corti M, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191-97.
3. Pahor M, Guralnik JM, Furberg CD, Carbonin PU, Havlik RJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-65.
4. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin PU, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-99.
5. Swales JD. Calcium antagonists. In: Swales JD, ed. Textbook of hypertension. Oxford: Blackwell Scientific Publications, 1994: 1111-14.
6. Naftilan AJ, Dzau VJ. Evaluation and management of hypertension. In: Kloner RA, ed. The guide to cardiology. New York: Le Jacq Communications, 1990: 409-36.
7. Sifton DW. Physicians' desk reference, 49th ed. Montvale: Medical Economics Data Production Company, 1995.
8. Alderman MH, Schoenbaum EE. Detection and treatment of hypertension at the worksite. N Engl J Med 1975; 293: 65-68.
9. Alderman MH, Davis TK. Hypertension control at the worksite. J Occup Med 1976; 18: 793-96.
10. Alderman MH, Madhavan S, Cohen HW. Antihypertensive drug therapy: the effect of JNC criteria on prescribing patterns and patient status through the first year. Am J Hypertens 1996; 9: 413-18.
11. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988; 148: 1023-38.
12. Mancia G, van Zweiten PA. How safe are calcium antagonists in hypertension and coronary heart disease? J Hypertens 1996; 14: 13-17.
13. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). JAMA 1996; 276: 785-91.
14. Meredith PA, Elliott HL. FDA guidelines on trough:peak ratios in the evaluation of antihypertensive agents. J Cardiovasc Pharmacol 1994; 23: S26-30 (suppl).
15. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-83.
16. The National Heart, Lung, and Blood Institute (NHBLI). New analysis regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. September, 1995.
17. Barnett AA. FDA committee rules calcium-channel blockers safe. Lancet 1996 347: 313.
18. Davis BR, Cutler JA, Gordon DJ, et al, for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9: 342-60.